EMA Authorised: Zypadhera (olanzapine pamoate) — CHEPLAPHARM Registration GmbH

View source ↗

Summary

The EMA has authorised Zypadhera (olanzapine pamoate) for schizophrenia, with CHEPLAPHARM Registration GmbH as the marketing authorisation holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Zypadhera (olanzapine pamoate)

Snippet

Status: Authorised. Therapeutic area: Schizophrenia. MAH: CHEPLAPHARM Registration GmbH. Decision date: 24/06/2026